Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 3/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | PRKCG | P05129 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459130 | 0.91 | AURKA (0.61) | SYKKDRNPC1MAPTMAPK1 | |
| SCHEMBL14024762 | 0.88 | SYK (0.49) | SYKKDRCDK1PRKCDEGFR | |
| SCHEMBL4875560 | 0.88 | KDR (0.69) | SYKKDRNPC1MAPTMAPK1 | |
| SCHEMBL849257 | 0.88 | SYK (0.62) | SYKKDRNPC1MAPTMAPK1 | |
| SCHEMBL3458531 | 0.85 | EGFR (0.72) | SYKKDRNPC1MAPTMAPK1 | |
| SCHEMBL4878601 | 0.85 | KDR (0.58) | SYKKDRIGF1RCDK1FGFR1 | |
| SCHEMBL14024364 | 0.83 | SYK (0.54) | SYKKDRNPC1MAPTMAPK1 | |
| SCHEMBL14024356 | 0.83 | KDR (0.66) | SYKKDRNPC1MAPTMAPK1 | |
| SCHEMBL4882766 | 0.83 | KDR (0.66) | SYKKDRNPC1MAPTMAPK1 | |
| SCHEMBL14024743 | 0.83 | AURKA (0.64) | SYKKDRNPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901143-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| US-8901143-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| EP-2154967-B9 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2154967-B9 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2154967-B1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-03-05 | — | — | EP | disclosed |
| EP-2154967-B1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-03-05 | — | — | EP | disclosed |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2013-03-14 | — | — | US | disclosed |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2013-03-14 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| WO-2008128231-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | SYK 2248/4885KDR 2/4885NPC1 3847/4885 |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | TYMS, KDR, FLT4 | SYK 2737/4885KDR 2/4885NPC1 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.